Answers are grounded in this paper and cite their sources.
Background Esophageal squamous cell carcinoma (ESCC) has a poor prognosis despite advancements in treatment. Neoadjuvant immunochemotherapy (nICT) has emerged as a promising strategy, demonstrating higher pathological complete response (pCR) rates than traditional neoadjuvant therapies. However, the long-term outcomes, recurrence patterns, and prognostic factors in patients with ESCC who achieve ypT0 following nICT and subsequent surgery remain incompletely understood, particularly regarding the risk of lymph node metastasis. Methods This retrospective study analyzed 887 patients with locally advanced ESCC who received nICT followed by esophagectomy between January 2020 and December 2024. Among them, 263 patients achieved ypT0, including 224 with ypT0N0 and 39 with ypT0N+ status. Patient characteristics, surgical outcomes, and pathological findings were also collected. Survival outcomes, recurrence patterns, and risk factors for lymph node metastasis were evaluated in this study. The primary endpoints were overall survival (OS) and disease-free survival (DFS) rates. Results The 1-year and 3-year OS rates were 93.8% and 82.1%, and the DFS rates were 90.8% and 76.3%, respectively. Subgroup analysis showed that patients with ypT0N0 had significantly better OS (94.6% and 85.6% at 1 and 3 years) and DFS (91.4% and 80.9%) than those with ypT0N+ (OS: 89.5% and 62.4%; DFS: 87.2% and 51.1%) (both P < 0.01). Recurrence occurred in 11.8% of patients. Univariable analysis indicated that smoking status and clinical M stage (cM) were associated with lymph node metastasis. Multivariate analysis revealed that ypN+ status was a significant adverse prognostic factor for both OS (HR: 3.340, 95% CI: 1.562-7.139, P = 0.002) and DFS (HR: 3.459, 95% CI: 1.852–6.461, P = 0.000). Adjuvant therapy was initially associated with improved OS and DFS; however, this effect was attenuated after adjusting for potential biases. Conclusions While achieving ypT0 after nICT confers favorable survival, residual nodal involvement (ypN+) identifies a high-risk subgroup with significantly poorer outcomes. Although adjuvant therapy showed an initial survival benefit, this association was not maintained in sensitivity analyses accounting for confounding factors. Future prospective validation is warranted to define the optimal postoperative strategy.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: